SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: Andreas Samson who wrote (19185)3/2/1999 4:33:00 PM
From: Mkilloran  Respond to of 23519
 
Andreas...there's no magic May 1st drop dead date,,,,

Astra has established a greater than 25% market for Muse in the UK.

If they can replicate that in the USA it will be very profitable.
In addition Vivus can haggle with Japan which is still open for the distribution of Muse. As well as future rights to Alibra.

It ain't over till it's over...



To: Andreas Samson who wrote (19185)3/2/1999 8:33:00 PM
From: VLAD  Read Replies (1) | Respond to of 23519
 
Andreas,

The stock price of Vivus currently tells us that the a domestic partner is nowhere in sight.

I expect that if the speculation regarding Astra/Zeneca partnering with and eventually buying out Vivus is true then we should know more for sure within 30 to 60 days after the merger is complete.

What if the Astra share holders vote not to merge come March 18th? It would seem unwise for either Zeneca or Astra to be negotiating seperate deals with other companies while they are in the midsts of a probable merger. I also assume they may have a verbal agreement not to negotiate any other deals until the merger is complete. A deal that is good for Astra alone may not be good for Astra/Zeneca and a deal that is good for Zeneca alone may also not be in the best interest of Astra/Zeneca. They are already being required to give up certain rights to certain drugs so they don't create a monopoly on certain drug types.